Evidence map›Paper›PMID 36287298›Full record

ArticleInvestigational new drugs2022

Tetra-arsenic tetra-sulfide enhances NK-92MI mediated cellular immunotherapy in all-trans retinoic acid-resistant acute promyelocytic leukemia.

Yanfeng Liu, Yan Jia, Yi Liu, Xuefeng Chen, Mei Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 59% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 citations in OpenAlex.

  1. CD3Frontiers in immunology · 2025
    Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Yanfeng LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, 410008, China. liu_xiaoyu2@163.com.ORCID 0000-0002-2610-3652
Yan JiaDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, 410008, China.ORCID 0000-0003-1048-9842
Yi LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, 410008, China.ORCID 0000-0003-2368-5703
Xuefeng ChenDepartment of Hematology, The Third Xiangya Hospital of Central South University, Changsha, 410013, China.ORCID 0000-0002-9893-9918
Mei ZhangDepartment of Hematology, The First Affiliated Hospital, Xi'an Jiaotong University, Xi'an 710061, China.
Central South University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CN

Funding

Beijing Xisike Clinical Oncology Research Foundation Y-SY2021QN-0010National Natural Science Foundation of China 81600135Natural Science Foundation of Hunan Province 2021JJ41011
6 · The paper itself

Abstract

Acute promyelocytic leukemia (APL) is liable to induce disseminated intravascular coagulation and has a high early mortality. Although the combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has significantly improved the complete remission rate, there are still some patients developed drug resistance. Growing evidence suggests that natural killer (NK) cell-mediated immunotherapy as a new treatment can help slow the progression of hematological malignancies. Previous studies also indicated that some tumors exhibited excellent responsiveness to NK cells in vitro. However, many clinical trial results showed that the anti-tumor effect of NK cells infusion alone was not ideal, which may be related to the inactivation of infiltrating NK cells caused by strong immunosuppression in tumor microenvironment, but the specific mechanism remains to be further explored. In the present study, we demonstrated that low doses of tetra-arsenic tetra-sulfide (As

Indexed as

ArsenicArsenicalsLeukemia, Promyelocytic, AcuteAnimalsImmunotherapyMiceOxidesSulfidesTretinoinTumor MicroenvironmentArsenicArsenicalsarsenic trisulfideOxidesSulfidesTretinoinAcute promyelocytic leukemiaImmunotherapyNatural killer group 2 member D ligandNK-92MIProgrammed death-1Tetra-arsenic tetra-sulfide

Identifiers

PMID36287298
OpenAlexW4307336215

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.